Stoke Therapeutics appoints Alexander “Bo” Cumbo to board after Edward Kaye resigns
STOK•Stoke Therapeutics appointed Alexander “Bo” Cumbo as a Class III director effective Sept. 23, 2026, after Edward M. Kaye resigned from the board and its Research and Development Committee. Cumbo’s term runs through the 2028 annual meeting.
1. Board changes
Stoke Therapeutics appointed Alexander “Bo” Cumbo as a Class III director effective Sept. 23, 2026, filling the vacancy created by Edward M. Kaye’s resignation on the same date. Kaye also stepped down from the board’s Research and Development Committee. Cumbo’s term runs through the 2028 annual meeting.
